1y return+0.9%S&P 500 +20.9%
3y return+22.5%S&P 500 +68.5%
5y return+30.1%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2019: $140 against $255 in the S&P 500.2
Tetragon Partners GP LtdS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| PATHUipath Inc | $336.4M | 54.8% | +22.8% |
| KGEIKolibri Global Energy Inc | $33.8M | 5.5% | |
| AUTLAutolus Therapeutics Ltd | $15.2M | 2.5% | |
| LYFTLyft Inc | $14.6M | 2.4% | |
| DFTXDefinium Therapeutics Inc | $13.5M | 2.2% | +43.5% |
| WKWorkiva Inc | $12.1M | 2.0% | |
| CXMSprinklr Inc | $11.4M | 1.8% | |
| MBXMbx Biosciences Inc | $11.2M | 1.8% | +39.9% |
| ALKTAlkami Technology Inc | $10.9M | 1.8% | New |
| CLDXCelldex Therapeutics Inc New | $10.8M | 1.8% | −7.0% |
| RLAYRelay Therapeutics Inc | $10.7M | 1.7% | +214.1% |
| ARWRArrowhead Pharmaceuticals In | $10.6M | 1.7% | +2.6% |
| Pharvaris N VCUSIP N69605108 | $10.2M | 1.7% | +33.4% |
| Alkermes PLCCUSIP G01767105 | $10.0M | 1.6% | +18.9% |
| IMVTImmunovant Inc | $9.9M | 1.6% | +17.1% |
| SLNSilence Therapeutics PLC | $8.4M | 1.4% | +21.3% |
| DYNDyne Therapeutics Inc | $7.9M | 1.3% | +38.2% |
| IONSIonis Pharmaceuticals Inc | $7.7M | 1.3% | +132.7% |
| AGIOAgios Pharmaceuticals Inc | $7.6M | 1.2% | +24.7% |
| HRMYHarmony Biosciences Hldgs In | $7.3M | 1.2% | +68.5% |
| KRYSKrystal Biotech Inc | $7.3M | 1.2% | |
| ANNXAnnexon Inc | $7.1M | 1.2% | −3.9% |
| CELCCelcuity Inc | $6.7M | 1.1% | New |
| Warner Bros Discovery IncCUSIP 934423104 | $6.7M | 1.1% | −72.9% |
| NKTRNektar Therapeutics | $6.1M | 1.0% | −15.6% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| MBXMbx Biosciences Inc | September 30, 2025 | +215.4% | $11.2M |
| AMLXAmylyx Pharmaceuticals Inc | June 30, 2025 | +180.2% | $5.4M |
| DFTXDefinium Therapeutics Inc | March 31, 2026 | +148.9% | $13.5M |
| ARWRArrowhead Pharmaceuticals In | September 30, 2025 | +136.3% | $10.6M |
| DYNDyne Therapeutics Inc | June 30, 2025 | +133.3% | $7.9M |
| IMVTImmunovant Inc | March 31, 2025 | +125.5% | $9.9M |
| Pharvaris N VCUSIP N69605108 | March 31, 2025 | +120.3% | $10.2M |
| KRYSKrystal Biotech Inc | September 30, 2025 | +110.5% | $7.3M |
| RLAYRelay Therapeutics Inc | March 31, 2026 | +88.0% | $10.7M |
| Alkermes PLCCUSIP G01767105 | June 30, 2025 | +83.1% | $10.0M |
Sold off last quarter
- PRAXPraxis Precision Medicines I was $5.1M
- Soleno Therapeutics IncCUSIP 834203309 was $3.4M
- AXSMAxsome Therapeutics Inc. was $3.4M
- MPLTMaplight Therapeutics Inc was $2.3M
- AARDAardvark Therapeutics Inc was $1.2M
- RAREUltragenyx Pharmaceutical In was $827K
- KPTIKaryopharm Therapeutics Inc was $295K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +5.4% | +14.8% |
| March 31, 2026 | −20.5% | −4.6% |
| December 31, 2025 | +15.9% | +2.4% |
| September 30, 2025 | +3.9% | +7.8% |
| June 30, 2025 | +12.2% | +10.5% |
| March 31, 2025 | −6.5% | −4.6% |
| December 31, 2024 | +8.5% | +2.1% |
| September 30, 2024 | +2.6% | +5.4% |
| June 30, 2024 | −28.3% | +4.0% |
| March 31, 2024 | +2.1% | +10.0% |
| December 31, 2023 | +39.6% | +11.2% |
| September 30, 2023 | +1.6% | −3.6% |
| June 30, 2023 | +3.8% | +8.3% |
| March 31, 2023 | +2.3% | +7.0% |
| December 31, 2022 | −2.1% | +7.1% |
| September 30, 2022 | +10.7% | −5.3% |
| June 30, 2022 | −7.6% | −16.5% |
| March 31, 2022 | +5.8% | −4.9% |
| December 31, 2021 | −3.4% | +10.7% |
| September 30, 2021 | −2.1% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Tetragon Partners GP Ltd Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1515070&type=13F-HR&dateb=&owner=include&count=40CIK 1515070
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1515070/000091957426005024/Filed August 13, 2026 · accession 0000919574-26-005024